|BioTime Announces Appointment of General Counsel|
May 22, 2019
|ALAMEDA, Calif.--(BUSINESS WIRE)--May 22, 2019--
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage
biotechnology company developing cellular therapies for unmet medical
needs, today announced that it has appointed Chase C. Leavitt as
BioTime’s General Counsel and Corporate Secretary.
“We’re extremely fortunate to have Chase join us and bring his extensive
public company experience as well as a strong track record to the role
|OncoCyte Presents Positive Results from R&D Validation Study of DetermaVu™ at the American Thoracic Society 2019 International Conference|
May 21, 2019
|Results were achieved using blood gene expression biomarkers alone and without the use of clinical parameters
Company remains on-track to make DetermaVu™ commercially available in 2H 2019
ALAMEDA, Calif., May 21, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today presented results from the Company’s R&D Validation study at the American Thoracic Society (ATS) 2019 International Conference, whi... |
|OncoCyte Provides Corporate Update and Reports First Quarter 2019 Financial Results|
May 14, 2019
|Completes successful Analytical Validation study and initiates CLIA Validation study
On track for commercial availability of DetermaVu™ in 2H 2019
Conference Call Today at 4:30 PM EDT
ALAMEDA, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, today reported financial and operating results for the first quarter ended March 31, 2019 and provided a corporate update.
“During t... |
View Committee Composition
Find the latest financial information
DISCLAIMER: You are about to review presentations, reports, filings and/or other materials regarding BioTime, Inc. (NYSE: MKT and TASE: BTX) that contain time-sensitive information. The information contained therein is only current as of the date thereof. BioTime expressly disclaims any obligation to review, update or correct these materials after the date thereof. BioTime may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.
Certain statements made on this website or in materials accessed in or through this section of our website are "forward-looking statements," which are subject to risks and uncertainties, and BioTime's actual results may differ (possibly materially) from those indicated in such statements.
|Data provided by Nasdaq. Minimum 15 minutes delayed.|